Anika Therapeutics (ANIK) Q4 2025 earnings summary

Executive summary

• Commercial Channel revenue grew 22% in Q4 and 15% for 2025, offsetting OEM declines driven by U.S. pricing pressures.

• International OA Pain Management delivered 28% Q4 growth and 12% for the year, with Integrity platform revenue more than doubling to $6M.

• Achieved 2025 revenue guidance and exceeded revised adjusted EBITDA targets; reaffirmed 2026 revenue and set new adjusted EBITDA guidance.

• Leadership transitions and organizational restructuring are expected to yield $2.5M in annualized headcount savings and $3M in stock-based compensation savings.

• Advanced product portfolio with Integrity procedure growth, Hyalofast PMA filing, and Cingal NDA progress.

Financial highlights

• Q4 2025 revenue was $30.6M, flat year-over-year; Commercial Channel up 22% to $13.3M, OEM down 12%.

• Full-year 2025 revenue was $112.8M, down 6% year-over-year; Commercial Channel up 15% to $48.4M, OEM down 17%.

• Q4 GAAP gross margin rose to 63%; full-year gross margin was 57%.

• Adjusted EBITDA for Q4 was $4.5M; full-year adjusted EBITDA was $5.3M.

• Operating cash flow for 2025 was $11.2M; free cash flow $4.4M; year-end cash was $57.5M with no debt.

Outlook and guidance

• 2026 revenue guidance: $114M–$122.5M (1%–9% growth year-over-year).

• Commercial Channel expected to grow 10%–20% ($53M–$58M); OEM Channel $61M–$64.5M (flat to modestly lower).

• Adjusted EBITDA margin targeted at 5%–10% of revenue for 2026.

• Free cash flow for 2026 expected to be in line with 2025, considering restructuring and ongoing investments.